房颤导管消融后继续口服抗凝的获益与风险
本研究基于日本全国行政理赔数据库回顾性分析2014年4月至2021年3月接受房颤导管消融且未复发患者,按CHADS2评分分层评估继续口服抗凝与血栓栓塞及大出血事件的关联。结果显示CHADS2≤1组继续抗凝大出血风险显著增加而血栓栓塞风险未显著降低,CHADS2≥3组继续抗凝血栓栓塞风险显著降低而大出血风险未显著增加。
要点
- CHADS2≤1者继续抗凝大出血HR 1.51,血栓栓塞风险未显著降低。
- CHADS2≥3者继续抗凝血栓栓塞HR 0.61,大出血风险未显著增加。
- 消融后6个月71%患者继续口服抗凝,高CHADS2组继续率更高。
核心结论
- 房颤导管消融后继续口服抗凝的获益与风险因CHADS2评分而异。
- 低血栓栓塞风险患者继续抗凝的大出血风险似乎超过血栓栓塞风险降低的获益。
研究设计与样本
- 回顾性研究,数据来自日本全国行政理赔数据库。
- 按指数消融后6个月是否继续口服抗凝分为两组,主要结局为6个月界标期后的血栓栓塞和大出血。
- 采用逆概率治疗加权分析,按CHADS2评分评估继续抗凝与结局的关联。
主要发现
- 71%患者在6个月时继续口服抗凝,高CHADS2组继续率高于低CHADS2组。
- 全部患者中2451例发生血栓栓塞(0.55/100人年),2367例发生大出血(0.53/100人年)。
临床怎么用
- 房颤消融后是否继续口服抗凝应结合CHADS2评分个体化决策。
- 低CHADS2评分患者继续抗凝需权衡大出血风险。
- 高CHADS2评分患者继续抗凝可能降低血栓栓塞风险。
局限性
- 回顾性观察性研究,可能存在残余混杂。
- 房颤复发基于行政数据评估,可能漏判。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Few recent large-scale studies have evaluated the risks and benefits of continuing oral anticoagulant (OAC) therapy after catheter ablation (CA) for atrial fibrillation (AF). This study evaluated the status of continuation of OAC therapy and the association between continuation of OAC therapy and thromboembolic and bleeding events according to the CHADS2 score. METHODS: This retrospective study included data from the Japanese nationwide administrative claims database of patients who underwent CA for AF between April 2014 and March 2021. Patients without AF recurrence assessed by administrative data of the treatment modalities were divided into two groups according to continuation of OAC therapy 6 months after the index CA. The primary outcomes were thromboembolism and major bleeding after a landmark period of 6 months. After inverse probability of treatment weighting analysis, the association between OAC continuation and outcomes was determined according to the CHADS2 score. RESULTS: Among 231 374 patients included, 69.7%, 21.6%, and 8.7% had CHADS2 scores of ≤1, 2, and ≥3, respectively. Of these, 71% continued OAC therapy at 6 months. The OAC continuation rate was higher in the high CHADS2 score group than that in the low CHADS2 score group. Among all patients, 2451 patients (0.55 per 100 person-years) had thromboembolism and 2367 (0.53 per 100 person-years) had major bleeding. In the CHADS2 score ≤1 group, the hazard ratio of the continued OAC group was 0.86 [95% confidence interval (CI): 0.74-1.01, P = .06] for thromboembolism and was 1.51 (95% CI: 1.27-1.80, P < .001) for major bleeding. In the CHADS2 score ≥3 group, the hazard ratio of the continued OAC group was 0.61 (95% CI: 0.46-0.82, P = .001) for thromboembolism and was 1.05 (95% CI: 0.71-1.56, P = 0.81) for major bleeding. CONCLUSIONS: This observational study suggests that the benefits and risks of continuing OAC therapy after CA for AF differ based on the patient's CHADS2 score. The risk of major bleeding due to OAC continuation seems to outweigh the risk reduction of thromboembolism in patients with lower thromboembolic risk.
引用
- Kanaoka, Nishida, Iwanaga, et al. Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks. Eur Heart J. 2024. PMID: 38117227. doi:10.1093/eurheartj/ehad798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。